Overview
p-ANCA, also known as MPO-ANCA or perinuclear anti-neutrophil cytoplasmic antibody, is an autoantibody directed against components inside neutrophils. In p-ANCA, the main target antigen is myeloperoxidase, an enzyme present in neutrophil granules. On immunofluorescence testing, these antibodies show a characteristic perinuclear staining pattern.
p-ANCA plays an important role in the diagnosis of autoimmune vasculitides and certain inflammatory diseases. These antibodies are part of a broader group called ANCA-associated vasculitides, which are rare autoimmune disorders characterized by inflammation and damage to blood vessels
Symptoms
Symptoms related to p-ANCA positivity depend on the organs involved and the severity of vascular inflammation. General symptoms are often nonspecific and may include fatigue, fever, loss of appetite, weight loss, and body aches.
When small blood vessels are affected, organ-specific symptoms appear. Kidney involvement may cause hematuria, proteinuria, and renal dysfunction. Lung involvement may present with cough, breathlessness, or hemoptysis. Skin involvement can cause purpura, rashes, or ulcers.
In some patients, p-ANCA is associated with inflammatory bowel disease, especially ulcerative colitis. These patients may present with chronic diarrhea, abdominal pain, and blood in the stools.
Causes
p-ANCA develops due to an autoimmune response in which the immune system produces antibodies against neutrophil cytoplasmic antigens. In this condition, antibodies specifically target myeloperoxidase, leading to abnormal activation of neutrophils.
Activated neutrophils damage the lining of blood vessels, resulting in inflammation, swelling, and narrowing of vessels. This process causes reduced blood flow and tissue injury, which leads to the clinical features of autoimmune vasculitis.
The exact trigger for antibody production is unknown. Genetic susceptibility, environmental factors, infections, and certain drugs are believed to contribute to the development of p-ANCA-associated diseases.
Risk Factors
Individuals with autoimmune conditions are at higher risk of developing p-ANCA positivity. Diseases such as microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, ulcerative colitis, and autoimmune liver diseases show strong associations.
Drug exposure is an important risk factor. Certain medications, including propylthiouracil and other drugs, can induce p-ANCA-associated vasculitis. Chronic inflammatory states may also increase risk.
A personal or family history of autoimmune disease increases susceptibility. p-ANCA may also be detected in some patients with systemic lupus erythematosus, rheumatoid arthritis, or chronic infections, although it is less specific in these conditions.
Prevention
There is no specific method to prevent the development of p-ANCA, as it arises from autoimmune mechanisms. Early recognition and testing in patients with unexplained systemic symptoms or suspected vasculitis help prevent organ damage.
Monitoring disease activity using antibody levels, along with clinical assessment, helps guide treatment decisions. Avoiding unnecessary exposure to drugs known to induce ANCA-associated vasculitis may reduce risk.
Prompt diagnosis and management of associated autoimmune and inflammatory diseases reduce complications. Regular follow-up is essential to detect relapses early and to assess response to therapy.
